ATE469887T1 - Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz - Google Patents

Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz

Info

Publication number
ATE469887T1
ATE469887T1 AT01983211T AT01983211T ATE469887T1 AT E469887 T1 ATE469887 T1 AT E469887T1 AT 01983211 T AT01983211 T AT 01983211T AT 01983211 T AT01983211 T AT 01983211T AT E469887 T1 ATE469887 T1 AT E469887T1
Authority
AT
Austria
Prior art keywords
drug resistance
substituted heterocyclic
heterocyclic compounds
multiple drug
treating multiple
Prior art date
Application number
AT01983211T
Other languages
English (en)
Inventor
Charles Degenhardt
David Eickhoff
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Application granted granted Critical
Publication of ATE469887T1 publication Critical patent/ATE469887T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/06—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/12—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT01983211T 2000-10-17 2001-10-16 Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz ATE469887T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24112700P 2000-10-17 2000-10-17
US09/740,643 US6376514B1 (en) 2000-10-17 2000-12-19 Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
PCT/US2001/042781 WO2002032869A2 (en) 2000-10-17 2001-10-16 Substituted heterocyclic compounds for treating multidrug resistance

Publications (1)

Publication Number Publication Date
ATE469887T1 true ATE469887T1 (de) 2010-06-15

Family

ID=26934029

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983211T ATE469887T1 (de) 2000-10-17 2001-10-16 Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz

Country Status (10)

Country Link
US (3) US6376514B1 (de)
EP (1) EP1326833B1 (de)
JP (1) JP4451060B2 (de)
AT (1) ATE469887T1 (de)
AU (1) AU2002214657A1 (de)
CA (1) CA2421008C (de)
DE (1) DE60142304D1 (de)
MX (1) MXPA03003490A (de)
PE (1) PE20020512A1 (de)
WO (1) WO2002032869A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60011817T2 (de) * 1999-12-30 2005-07-14 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl und -tetrahydropyridyl-derivate
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
KR100503161B1 (ko) * 2002-07-18 2005-07-25 한미약품 주식회사 신규한 ｐ-당단백질 저해제, 그의 제조방법 및 이를유효성분으로 하는 경구투여용 조성물
SG170767A1 (en) 2005-12-23 2011-05-30 Zealand Pharma As Modified lysine-mimetic compounds
ATE469649T1 (de) * 2006-03-23 2010-06-15 Actelion Pharmaceuticals Ltd Antibiotische cyclohexyl- oder piperidinylcarboxamid-derivate
WO2009110955A2 (en) * 2008-02-29 2009-09-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonists of human pregnane x receptor and uses thereof
WO2018202865A1 (en) 2017-05-05 2018-11-08 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE563610R (fr) 1957-12-30 1960-06-17 Morren H Derives du 2-propanol.
US4029801A (en) 1970-09-03 1977-06-14 John Wyeth & Brother Limited Pharmaceutical compositions and methods of treating hypertension
FR2267104A1 (en) 1974-04-12 1975-11-07 Ferlux Labo Sa Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines
PT66682B (pt) 1976-06-18 1978-11-15 Ind Biolog Francaise /(quinolyl-4)-propyl-1/-4 piperidines leur preparation et leur utilisation comme medicaments /(quinolyl-4)-propyl/-4 piperidines leur preparation et leur utilisation comme medicaments
GB1583811A (en) 1977-05-09 1981-02-04 Laroche Navarron Sa Chromene derivatives
NL7908031A (nl) 1979-11-01 1981-06-01 Acf Chemiefarma Nv Nieuwe chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werk- wijze voor het bereiden van deze verbindingen.
FR2471981A1 (fr) 1979-12-21 1981-06-26 Pharmindustrie Nouveaux derives de la (piperidyl-4)-2 (quinolyl-4)-1 ethanone, produits intermediaires et procedes pour leur preparation, et leur utilisation comme medicaments
US4806552A (en) 1980-03-01 1989-02-21 John Wyeth & Brother, Limited Pyridyl- and/or pyridoyl-(piperid-4-yl) ureas and analogues thereof
IL62240A0 (en) 1980-03-06 1981-05-20 Acf Chemiefarma Nv Novel quinoline derivatives,pharmaceutical compositions containing such compounds,and methods for the preparation of these compounds
US4442107A (en) 1980-03-06 1984-04-10 Acf Chemiefarma N.V. Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods for treating cardiovascular conditions with them
US4443453A (en) 1980-03-06 1984-04-17 Acf Chemiefarma N.V. Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods for treating cardiovascular conditions with them
FR2485014A1 (fr) 1980-06-20 1981-12-24 Pharmindustrie Nouveaux derives de (quinolyl-2, -3 ou -4)-1 (piperidyl ou pyrrolidinyl-2 ou -3)-2 ou -3 ethanone ou propanone, procedes pour leur preparation, et leur utilisation comme medicaments
FR2495470A1 (fr) 1980-12-05 1982-06-11 Pharmindustrie Nouveaux medicaments a base de derives de (quinolyl-4)-1 (piperidyl-4)-2 ethanol ou (quinolyl-4)-1 (piperidyl-4)-3 propanol
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4584303A (en) 1984-04-09 1986-04-22 The Boc Group, Inc. N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds
DE3524955A1 (de) * 1984-07-19 1986-01-30 Sandoz-Patent-GmbH, 7850 Lörrach 3-aminopropoxyaryl-derivate, ihre herstellung und sie enthaltende arzneimittel
GB2163150B (en) * 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
US4911923A (en) * 1985-06-27 1990-03-27 Conoco Inc. Biocide for petroleum operations
US4963553A (en) 1986-10-16 1990-10-16 American Cyanamid Co. 4-[(substituted) alkylcarbonyl]-4,5-dihydro- and -4,5,6,7-tetrahydro-7-[(substituted)phenyl]pyrazolo[1,5-a]pyrimidines
JPS63135381A (ja) 1986-11-26 1988-06-07 Kyorin Pharmaceut Co Ltd 多剤耐性癌細胞に対する感受性増強剤及びその製造方法
US4916142A (en) 1987-02-02 1990-04-10 Boc, Inc. N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and their use as analgesics
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5928637A (en) 1987-06-16 1999-07-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of inducing multidrug resistance using human MDR1 cDNA
US5013742A (en) 1987-11-02 1991-05-07 Boc, Inc. 4-phenyl-4-N-(phenyl) amido piperidine derivatives and pharmaceutical compositions and method employing such compounds
US4980351A (en) 1987-11-04 1990-12-25 Warner-Lambert Company 3-aminopropoxyaryl derivatives having cardiotonic and antihypertensive use and compositions thereof
US4791120A (en) 1987-12-31 1988-12-13 The Boc Group, Inc. 4-heteropentacyclic-4-[N-(phenyl)amino] piperidine derivatives and pharmaceutical compositions and method employing such compounds
DK733788A (da) 1988-01-14 1989-07-15 Fujisawa Pharmaceutical Co Indolylpiperidinderivater og fremgangsmaade til fremstilling deraf
US5216172A (en) 1988-02-24 1993-06-01 Ajinomoto Co., Inc. 1,4-dihydropyridine-4-aryl-2,6-dimethyl-3,5-dicarboxylates useful as agents against drug resistant tumor cells
CA1331613C (en) 1988-07-28 1994-08-23 Nikken Chemicals Co., Ltd. 1,4-dihydropyridine derivative
CA1334752C (en) 1988-08-02 1995-03-14 Ryozo Sakoda Drug effect-enhancing agent for antitumor drug
JP2850376B2 (ja) 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
DE3832362A1 (de) 1988-09-23 1990-03-29 Sandoz Ag Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung
US5204348A (en) * 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
JPH0699399B2 (ja) 1988-10-06 1994-12-07 三井東圧化学株式会社 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
GB8914062D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5098915A (en) 1989-09-05 1992-03-24 G. D. Searle & Co. Substituted N-benzylpiperidine amides
US5182293A (en) 1989-11-13 1993-01-26 Merrell Dow Pharmaceuticals Inc. Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
ZA908852B (en) 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
ZA908936B (en) 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with quinolyloxazole-2-ones
US5190957A (en) 1989-11-13 1993-03-02 Merrell Dow Pharmaceuticals Inc. Treatment of multi-drug resistant tumors with quinolyl-and isoquinolyloxazole-2-ones
WO1991009846A1 (de) 1989-12-22 1991-07-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue dihydropyridine
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
US5190946A (en) 1990-02-23 1993-03-02 Hoffmann-La Roche Inc. Methods and compounds
US5114919A (en) 1990-02-26 1992-05-19 Merck & Co., Inc. Adjuncts in cancer chemotherapy
US4996321A (en) 1990-02-26 1991-02-26 Merck & Co., Inc. Dibenzo[a,d]cycloheptenylidene compounds
US5272159A (en) 1990-02-26 1993-12-21 Merck & Co., Inc. Adjuncts in cancer chemotherapy
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5514664A (en) 1990-05-26 1996-05-07 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridines for application in combatting resistance to drugs
US5189036A (en) 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
US5196799A (en) 1990-07-12 1993-03-23 Drexel University Method and apparatus for testing a protective barrier material for pinholes and tear strength
DK178490D0 (da) 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
FR2667243B1 (fr) 1990-09-27 1994-11-04 Adir Utilisation de s derives de la triazine et de la pyrimidine pour l'obtention de medicaments reversant la resistance aux agents anticancereux et antimalariques.
FR2669029B1 (fr) 1990-11-14 1994-09-02 Adir Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5416091A (en) 1990-12-18 1995-05-16 Burroughs Wellcome Co. Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5693767A (en) 1991-01-22 1997-12-02 Harrier Inc. Glycoside derivatives of acetaminophen
FR2673627B1 (fr) 1991-03-07 1993-05-07 Adir Triazines et pyrimidines trisubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
UA39849C2 (uk) 1991-03-26 2001-07-16 Ф.Хоффманн-Ля Рош Аг ПОХІДНІ N-АЦИЛ-<font face="Symbol">a</font>-АМІНОКИСЛОТИ АБО ЇХ ФІЗІОЛОГІЧНО ПРИЙНЯТНІ СОЛІ, ПРОСТІ АБО СКЛАДНІ ЕФІРИ, АМІДИ АБО ЇХ ГІДРАТИ ЯК ФАРМАЦЕВТИЧНО АКТИВНІ РЕЧОВИНИ
US5939420A (en) 1991-04-08 1999-08-17 Duquesne University Of The Holy Ghost Pyrrolo 2,3d!derivatives
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
DE4113505A1 (de) 1991-04-25 1992-10-29 Thomson Brandt Gmbh Verfahren zur bildsignalcodierung
US5292757A (en) 1991-04-26 1994-03-08 Ajinomoto Company, Inc. 1,4-dihydropyridine compounds useful as reverse resistance agents
US5620971A (en) 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5723459A (en) * 1991-05-09 1998-03-03 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
WO1992020661A1 (en) 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
ZA925185B (en) 1991-07-18 1993-04-29 Hoffmann La Roche Dithianes.
WO1993003729A1 (en) 1991-08-12 1993-03-04 Research Corporation Technologies, Inc. N-substituted phenoxazines for treating multidrug resistant cancer cells
AU653060B2 (en) 1991-08-23 1994-09-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative and platelet agglutination inhibitor
CA2074061A1 (en) 1991-08-26 1993-02-27 Ivo Monkovic Benzamide multidrug resistance reversing agents
US5173486A (en) 1991-08-26 1992-12-22 Bristol-Myers Squibb Company Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
ES2084176T3 (es) 1991-09-05 1996-05-01 Pharno Wedropharm Gmbh Derivados de sulfonamidas aromaticas, su uso como inhibidores de enzimas y composiciones farmaceuticas que los contienen.
GB9119983D0 (en) 1991-09-19 1991-11-06 Erba Carlo Spa Dihydropyridine derivatives useful in antitumor therapy
US5536722A (en) 1991-11-12 1996-07-16 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
FR2686879B1 (fr) 1992-02-05 1994-03-18 Adir Cie Nouveaux composes de 1,4-dihydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant.
JPH07503728A (ja) 1992-02-06 1995-04-20 メレルダウファーマスーティカルズ　インコーポレイテッド テトラアリールエチレン類による多剤耐性の逆転
CA2129337A1 (en) 1992-02-19 1993-09-02 Jotham W. Coe Heterocyclic compounds for enhancing antitumor activity
US5605896A (en) 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE69310367T2 (de) 1992-07-10 1997-08-14 Glaxo Lab Sa Anilide-derivate
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
AU5127893A (en) 1992-09-11 1994-04-12 Research Corporation Technologies, Inc. 1,2 dihydro-3-h-dibenz(de,h) isoquinoline 1,3 dione and their use as anticancer agents
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
IT1255704B (it) 1992-09-30 1995-11-10 Boehringer Mannheim Italia Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
CA2146548A1 (en) 1992-11-09 1994-05-26 Giorgio Attardo Antineoplastic heteronaphthoquinones
WO1994014809A1 (de) 1992-12-23 1994-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Anellierte uracilderivate
JPH06211664A (ja) 1993-01-20 1994-08-02 Pola Chem Ind Inc 薬剤に対する感受性回復剤
ATE150748T1 (de) 1993-01-21 1997-04-15 Merrell Pharma Inc Als mittel gegen mehrfach resistente tumorenverwendbare diarylalkylpiperidine
CA2155759A1 (en) 1993-03-29 1994-10-13 Bernd Janssen 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
US5336685A (en) 1993-04-12 1994-08-09 Sloan-Kettering Institute For Cancer Research Use of flavonoids to treat multidrug resistant cancer cells
WO1994024105A1 (en) 1993-04-15 1994-10-27 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
DE4315153A1 (de) 1993-05-07 1994-11-10 Hoechst Schering Agrevo Gmbh Substituierte Chinolinverbindungen, Verfahren zu deren Herstellung, diese enthaltende Mittel und deren Verwendung als Safener
CA2165176A1 (en) 1993-06-18 1995-01-05 Samuel L. Graham Inhibitors of farnesyl-protein transferase
US5409690A (en) 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
AU691829B2 (en) 1993-07-16 1998-05-28 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
WO1995005824A1 (en) 1993-08-24 1995-03-02 Smithkline Beecham Corporation Aaptamines and method of use thereof
JPH07126165A (ja) 1993-10-29 1995-05-16 Masao Oguro 腫瘍治療剤
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
WO1995021381A1 (en) 1994-02-01 1995-08-10 The Rockefeller University Methods and agents for measuring and controlling multidrug resistance
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
US5610165A (en) 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5763443A (en) * 1994-04-05 1998-06-09 Universiteit Van Pretoria MDR resistance treatment and novel pharmaceutically active riminophenazines
JPH10501526A (ja) * 1994-06-01 1998-02-10 チバ−ガイギー アクチェンゲゼルシャフト 多薬物耐性に対する作用物質としてのカルバゾール誘導体
WO1995032975A1 (en) 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
JPH10500394A (ja) 1994-06-01 1998-01-13 チバ−ガイギー アクチェンゲゼルシャフト 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするための多環式ラクタム誘導体
US5571687A (en) 1994-06-07 1996-11-05 Duke University Modulators of multidrug resistance transporters
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US5670521A (en) 1994-08-05 1997-09-23 Merrell Pharmaceuticals Inc. Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives
US5543428A (en) 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
IL115582A0 (en) 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
EP0709384B1 (de) 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
IL115685A (en) 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
GB9426090D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426071D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
JPH0912577A (ja) 1995-04-28 1997-01-14 Takeda Chem Ind Ltd カルバペネム化合物、その製造法および剤
US5726184A (en) 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US5756527A (en) * 1995-06-07 1998-05-26 Ontogen Corporation Imidazole derivatives useful as modulators of multi drug resistances
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
CA2179574A1 (en) 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
US5827877A (en) 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
US5834014A (en) 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US5670508A (en) 1995-10-25 1997-09-23 National Science Council 2-amino-6-alkyl-5-(4-substituted-1-piperazinyl) pyrimidin-4-ones, the preparation and use thereof
WO1997017069A1 (en) 1995-11-07 1997-05-15 Eli Lilly And Company Methods for treating resistant tumors
US6011069A (en) 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
DE19548797A1 (de) 1995-12-27 1997-07-03 Thomae Gmbh Dr K Substituierte 2-Amino-imidazole, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2218660T3 (es) 1996-01-16 2004-11-16 Bristol-Myers Squibb Company Inhibidores aromaticos conformacionalmente restringidos de la proteina de transferencia de trigliceridos microsomales y procedimiento.
US5733911A (en) 1996-01-26 1998-03-31 Hitachi Chemical Co., Ltd. Method for inducing death of neoplastic cells using piperazne derivatives
DE69700887T2 (de) 1996-01-31 2000-06-29 Nisshin Flour Milling Co., Ltd. Isoprenderivate
AU1597197A (en) 1996-02-01 1997-08-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Thienoquinolines
TW527186B (en) 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5885786A (en) * 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
AU2908997A (en) 1996-05-24 1998-01-05 University Of Pretoria, The Use of riminophenazines as antimicrobial and antimalarial agents
EP0812830A1 (de) 1996-06-14 1997-12-17 Ontogen Corporation Modulatoren von Mehrfachresistenz gegen Medikamente
WO1997048689A1 (en) 1996-06-17 1997-12-24 Eli Lilly And Company Drug resistance and multidrug resistance modulators
US5869650A (en) 1996-06-21 1999-02-09 Fox Chase Cancer Center Dendroamide compounds and their use in chemosensitizing multidrug resistant cells
DK0927168T3 (da) 1996-08-28 2003-03-10 Procter & Gamble 1,3-diheterocykliske metalloproteaseinhibitorer
PL331854A1 (en) 1996-08-28 1999-08-16 Procter & Gamble Phosphinamides as inhibitors of metaloprotease matrix
GB2317030A (en) 1996-08-30 1998-03-11 Xenova Ltd Defining a pharmacophore for the design of MDR modulators
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
KR20000057157A (ko) 1996-11-22 2000-09-15 피터 지. 스트링거 약물 내성 및 복합 약물 내성 조절제
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
CA2198645A1 (en) 1997-02-27 1998-08-27 Peter Juranka Use of dillapiol and its analogues and derivatives to affect multidrug resistant cells
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
GB9710612D0 (en) 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
US5776939A (en) * 1997-06-12 1998-07-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
FR2765222B1 (fr) 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
WO1999010340A1 (en) 1997-08-29 1999-03-04 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
AU1146099A (en) 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
ZA9810210B (en) 1997-11-10 1999-07-14 Searle & Co Use of alkylated iminosugars to treat multidrug resistance.
EP1034164B1 (de) 1997-11-24 2004-05-19 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6066673A (en) 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
GB9812189D0 (en) 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
TWI250152B (en) 1998-07-21 2006-03-01 Eisai Co Ltd N,N-substituted cyclic amine compounds used as calcium antagonizer
US6329872B1 (en) 1998-08-14 2001-12-11 Nortel Networks Limited Charge pump circuit for a phase locked loop
US6307049B1 (en) * 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
ES2221440T3 (es) 1998-10-16 2004-12-16 Daiichi Suntory Pharma Co Ltd Derivados de acido aminofenoxiacetico como neuroprotectores.
KR20010081115A (ko) 1998-12-18 2001-08-27 둘락 노먼 씨. 파르네실 단백질 트랜스퍼라제 억제제
US6200990B1 (en) 1998-12-21 2001-03-13 Alcon Laboratories, Inc. Neuroprotective agents having antioxidant and NMDA antagonist activity
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
HUP9902628A3 (en) 1999-08-02 2001-07-30 Ivax Gyogyszerki Kft Angiogenesis inhibiting borrelidin derivatives, their use and pharmaceutical compositions containing them
US6403610B1 (en) 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6258526B1 (en) 2000-01-19 2001-07-10 M.D.R. Test Ltd Ex-vivo test kit for testing the effectiveness of reversers of multidrug resistance
EA200200847A1 (ru) 2000-02-11 2003-02-27 Вертекс Фармасьютикалз Инкорпорейтед Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
CN101230034A (zh) 2000-03-06 2008-07-30 阿卡蒂亚药品公司 用于治疗5-羟色胺相关性疾病的氮杂环化合物
US7018988B2 (en) 2000-03-27 2006-03-28 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6564304B1 (en) * 2000-09-01 2003-05-13 Ati Technologies Inc. Memory processing system and method for accessing memory including reordering memory requests to reduce mode switching
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US20020119979A1 (en) * 2000-10-17 2002-08-29 Degenhardt Charles Raymond Acyclic compounds and methods for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US20020091120A1 (en) * 2000-10-17 2002-07-11 Degenhardt Charles Raymond 2-substituted heterocyclic compounds for treating multidrug resistance
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
US20020128269A1 (en) * 2000-10-17 2002-09-12 Degenhardt Charles Raymond Substituted heterocyclic compounds for treating multidrug resistance
US20020115659A1 (en) * 2000-10-17 2002-08-22 Degenhardt Charles Raymond Compounds having heterocyclic groups containing two nitrogen atoms for treating multidrug resistance
US20020082262A1 (en) * 2000-10-17 2002-06-27 Degenhardt Charles Raymond Substituted bicyclic compounds for treating multidrug resistance
AU2002233598B2 (en) 2001-02-28 2007-06-14 Ge Healthcare Niagara Inc. An imaging fluorometer for time resolved fluorescence
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them

Also Published As

Publication number Publication date
MXPA03003490A (es) 2003-07-14
JP4451060B2 (ja) 2010-04-14
DE60142304D1 (de) 2010-07-15
EP1326833B1 (de) 2010-06-02
WO2002032869A8 (en) 2003-11-20
EP1326833A2 (de) 2003-07-16
CA2421008C (en) 2009-01-06
JP2004511546A (ja) 2004-04-15
WO2002032869A2 (en) 2002-04-25
AU2002214657A1 (en) 2002-04-29
PE20020512A1 (es) 2002-07-17
US7135483B2 (en) 2006-11-14
US20060223853A1 (en) 2006-10-05
CA2421008A1 (en) 2002-04-25
US7476680B2 (en) 2009-01-13
WO2002032869A3 (en) 2002-08-22
US6376514B1 (en) 2002-04-23
US20020099215A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
ATE553086T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung der multipler medikamentenresistenz
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
WO2005021495A3 (en) Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
MXPA05009367A (es) Antagonistas del receptor opioide.
WO2004000808A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
SE0104250D0 (sv) Heterocyclic compounds
DE60302157D1 (de) Opioidrezeptorantagonisten
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
DE602004031410D1 (de) Inden derivate als pharmazeutika
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE469887T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
SE0203303D0 (sv) Novel Compounds
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
SE0203300D0 (sv) Novel Compounds
SE0104326D0 (sv) Therapeutic heterocycles

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties